H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fibrodysplasia Ossificans Progressiva. These milestones boost Mirum's growth prospects and open new revenue streams. Despite current shares trading at $87.10, the new target suggests significant upside potential for investors.
Mirum Pharmaceuticals' recent price target increase to $195 provides context for readers interested in pharmaceutical developments. For readers following the health sector, here is Pluang's market snapshot as of Sep 29, 2026 01:52 WIB: out of 100 priced health-sector US stocks tradable on Pluang, 57 rose and 43 fell. Notable movers include ACADIA Pharmaceuticals Inc. (ACAD) at USD 20.17 with a 1-day change of -2.47% and a Pluang order activity of 3% Sell / 97% Buy, Viatris Inc (VTRS) at USD 18.27 with a 1-day change of +2.44% and 0% Sell / 100% Buy, and Abeona Therapeutics Inc (ABEO) at USD 5.27 with a 1-day change of -2.41%.
Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...
A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...
Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stabl...
Conagra Brands is set to report Q1 earnings with analysts forecasting a 1.4% revenue decline to about $2.59 billion due to weak consumer spending and inflation. Earnings per share are expected to drop 20.5% to $0.31, reflecting margin pressures and a...
Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...
